Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program
Shots: Accent to receive ~$446M including up front, pre-clinical, clinical, regulatory, and sales-based milestone along with royalties Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program The collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities to develop and commercialize transformative oncology medicines for the treatment of AML […]